{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:19Z","timestamp":1788582439750,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1124\/dmd.111.038067","type":"journal-article","created":{"date-parts":[[2011,3,26]],"date-time":"2011-03-26T03:01:18Z","timestamp":1301108478000},"page":"1139-1148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs"],"prefix":"10.1016","volume":"39","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magang","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.038067_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0091270004271969","article-title":"Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways","volume":"45","author":"Adams","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138920009788498978","article-title":"Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction","volume":"10","author":"Almond","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.111.038067_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00563105","article-title":"The effect of rifampicin on norethisterone pharmacokinetics","volume":"15","author":"Back","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-7824(80)90125-0","article-title":"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women","volume":"21","author":"Back","year":"1980","journal-title":"Contraception"},{"key":"10.1124\/dmd.111.038067_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0009-9236(97)90134-X","article-title":"Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate","volume":"61","author":"Borin","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1124\/dmd.109.027029","article-title":"In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America perspective","volume":"37","author":"Chu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/AAC.30.1.42","article-title":"Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination","volume":"30","author":"Drusano","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.111.038067_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 \u03bcg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib16","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.038067_bib17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.111.038067_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","article-title":"The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine","volume":"58","author":"Gomez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib21","first-page":"1329","article-title":"The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module","volume":"56","author":"Goodwin","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity [published erratum appears in Clin Pharmacol Ther 75:249, 2004]","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.clpt.6100222","article-title":"Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo","volume":"83","author":"Gurley","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/clpt.1992.171","article-title":"Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction","volume":"52","author":"Hebert","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03602530601093489","article-title":"Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies","volume":"39","author":"Hewitt","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.038067_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(25)08415-6","article-title":"The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 269:2088, 1993]","volume":"269","author":"Honig","year":"1993","journal-title":"JAMA"},{"key":"10.1124\/dmd.111.038067_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.111.038067_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/mend.14.1.0409","article-title":"The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution","volume":"14","author":"Jones","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1124\/dmd.111.038067_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.111.038067_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/dmd.107.017418","article-title":"HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2133\/dmpk.20.236","article-title":"The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes","volume":"20","author":"Kato","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.111.038067_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","article-title":"Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1124\/dmd.108.025734","article-title":"Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay","volume":"37","author":"Kozawa","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01789.x","article-title":"Evidence of an interaction between nifedipine and nafcillin in humans","volume":"55","author":"Lang","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1099-0461(2000)14:4<177::AID-JBT1>3.0.CO;2-4","article-title":"Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes","volume":"14","author":"LeCluyse","year":"2000","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.111.038067_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11095-006-0277-7","article-title":"CYP induction-mediated drug interactions: in vitro assessment and clinical implications","volume":"23","author":"Lin","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.111.038067_bib39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.111.038067_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","article-title":"Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping","volume":"66","author":"Link","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","article-title":"Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes","volume":"31","author":"Madan","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.103.061713","article-title":"Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line","volume":"309","author":"Mills","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038067_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00007890-198503000-00022","article-title":"Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin","volume":"39","author":"Modry","year":"1985","journal-title":"Transplantation"},{"key":"10.1124\/dmd.111.038067_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0300-483X(00)00300-0","article-title":"Use of the nuclear receptor PXR to predict drug interactions","volume":"153","author":"Moore","year":"2000","journal-title":"Toxicology"},{"key":"10.1124\/dmd.111.038067_bib45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1345\/aph.18261","article-title":"Potential fluconazole-induced carbamazepine toxicity","volume":"33","author":"Nair","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.111.038067_bib46","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0731-7085(97)00044-7","article-title":"The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine","volume":"15","author":"Ndanusa","year":"1997","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.111.038067_bib47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/clpt.1987.125","article-title":"The effect of antipyrine and rifampin on the metabolism of diazepam","volume":"42","author":"Ohnhaus","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/00498250110055479","article-title":"Carbamazepine: a \u2018blind\u2019 assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems","volume":"31","author":"Pelkonen","year":"2001","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.038067_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038067_bib50","first-page":"20","article-title":"Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine","volume":"57","author":"Rapeport","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/dmd.111.038067_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0009-9236(95)90244-9","article-title":"Effects of felbamate on the pharmacokinetics of phenobarbital","volume":"58","author":"Reidenberg","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib52","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1124\/dmd.106.010132","article-title":"Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction","volume":"34","author":"Ripp","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.111.038067_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.2006.02707.x","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects","volume":"63","author":"Saari","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(25)23442-5","article-title":"Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a \u201ccocktail\u201d study design","volume":"249","author":"Schellens","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038067_bib56","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1124\/dmd.108.020602","article-title":"Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction","volume":"36","author":"Shou","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib57","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.111.038067_bib58","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","first-page":"1787","article-title":"Design and optimization of dosage regimens; pharmacokinetic data","author":"Thummel","year":"2006"},{"key":"10.1124\/dmd.111.038067_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","article-title":"Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation","volume":"304","author":"Tirona","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038067_bib60","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib61","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0091270006292628","article-title":"Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers","volume":"46","author":"Uchida","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib62","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/dmd.111.038067_bib63","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","article-title":"Rifampin reduces plasma concentrations and effects of zolpidem","volume":"62","author":"Villikka","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038067_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2125.1999.00953.x","article-title":"Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations","volume":"48","author":"Von Moltke","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038067_bib65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib66","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1124\/dmd.108.025494","article-title":"Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator","volume":"37","author":"Xu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038067_bib67","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881106065907","article-title":"Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA","volume":"20","author":"Yang","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1124\/dmd.111.038067_bib68","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.111.038067_bib69","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.111.038067_bib70","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jps.10179","article-title":"Inhibition-based metabolic drug-drug interactions: predictions from in vitro data","volume":"91","author":"Yao","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.111.038067_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","article-title":"Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study","volume":"49","author":"Zhao","year":"2009","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624057994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624057994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.038067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:43:14Z","timestamp":1739904194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624057994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0090955624057994"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.038067","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.038067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}